Undervalued Zai Lab on Licensing Binge to Boost Cancer Treatment Portfolio

With $860 million in new cash from a recent share sale, company seeks to accelerate approval and rollout of new cutting-edge treatments from abroad Key takeaways: Zai Lab’s revenue should continue to surge on new product approvals and inclusion of a core product on the National Reimbursement Drug List Company’s losses could continue to balloon as it pursues expensive new licensing deals at the cost of near-term profits By Richard Barbarossa Cancer and autoimmune drug specialist Zai Lab Ltd.(Nasdaq: ZLAB; 9688.HK) is poised to accelerate approval of new medicines and…

Read MORE »